The REMS program for vandetanib in the treatment of patients with medullary thyroid cancer has been removed by the FDA.

Leaders in oncology nursing and advanced practice spotlight the essential role of advanced practice providers in oncology.

The FDA has approved imlunestrant for the treatment of patients with ESR1-mutated ER+, HER2- metastatic breast cancer.

Caleb Raine, PA-C explains what BCMA is and why it is a common bispecific antibody target in multiple myeloma.

Subcutaneous pembrolizumab has been approved across all indications, cutting chair and administration times with a median ...

When treating patients with bladder cancer using gemcitabine intravesical system, regular AE monitoring is necessary, said ...

BC, AOCNP, explains how ctDNA can inform prognosis, monitor disease progression, and guide treatment decisions in oncology.

In an interview with Oncology Nursing News, Kirschner, who serves as the director of program development at the Cancer ...

Explore stories of oncology nurses who forge connections with patients, transforming challenges into triumphs in cancer care.

C, OCN, discusses how patient comorbidities and adverse effect profiles guide CDK4/6 inhibitor choice in the first-line setting.

The NCCN has added revumenib (Revuforj) to its guidelines for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) harboring NPM1 mutations, accordin ...